Related references
Note: Only part of the references are listed.Is the Risk of Ovarian Malignancy Algorithm Better Than Other Tests for Predicting Ovarian Malignancy in Women with Pelvic Masses?
Marut Yanaranop et al.
GYNECOLOGIC AND OBSTETRIC INVESTIGATION (2017)
Combining a symptom index, CA125 and HE4 (triple screen) to detect ovarian cancer in women with a pelvic mass
Barbara A. Goff et al.
GYNECOLOGIC ONCOLOGY (2017)
Subjective assessment versus ultrasound models to diagnose ovarian cancer: A systematic review and meta-analysis
E. M. J. Meys et al.
EUROPEAN JOURNAL OF CANCER (2016)
HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: An Italian multicenter study
Cesare Romagnolo et al.
GYNECOLOGIC ONCOLOGY (2016)
HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population
Anthony Richards et al.
AUSTRALIAN & NEW ZEALAND JOURNAL OF OBSTETRICS & GYNAECOLOGY (2015)
Development of a multimarker assay for differential diagnosis of benign and malignant pelvic masses
Xinliang Chen et al.
CLINICA CHIMICA ACTA (2015)
ROMA, an algorithm for ovarian cancer
Anita Monika Chudecka-Glaz
CLINICA CHIMICA ACTA (2015)
Distinguishing benign from malignant pelvic mass utilizing an algorithm with HE4, menopausal status, and ultrasound findings
Sarikapan Wilailak et al.
JOURNAL OF GYNECOLOGIC ONCOLOGY (2015)
Management of presumed benign ovarian tumors: updated French guidelines
J. -L. Brun et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2014)
Prognostic Value of Serum HE4 Levels and Risk of Ovarian Malignancy Algorithm Scores at the Time of Ovarian Cancer Diagnosis
Jeroen Kaijser et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2014)
Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis
Jiwen Wang et al.
TUMOR BIOLOGY (2014)
Borderline Ovarian Tumors and Diagnostic Dilemma of Intraoperative Diagnosis: Could Preoperative He4 Assay and ROMA Score Assessment Increase the Frozen Section Accuracy? A Multicenter Case-Control Study
Salvatore Gizzo et al.
BIOMED RESEARCH INTERNATIONAL (2014)
Comparison of serum human epididymis protein 4 and carbohydrate antigen 125 as markers in ovarian cancer: A meta-analysis
Shuai Zhen et al.
MOLECULAR AND CLINICAL ONCOLOGY (2014)
Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response
Elham O. Hamed et al.
DIAGNOSTIC PATHOLOGY (2013)
Human epididymis protein 4 for differential diagnosis between benign gynecologic disease and ovarian cancer: a systematic review and meta-analysis
JiaYing Lin et al.
EUROPEAN JOURNAL OF OBSTETRICS & GYNECOLOGY AND REPRODUCTIVE BIOLOGY (2013)
Ovarian tumor markers of presumed benign ovarian tumors
N. Lahlou et al.
JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION (2013)
Clinical practice guidelines: Presumed benign ovarian tumors - Aims, methods, and organization
J. -L. Brun et al.
JOURNAL DE GYNECOLOGIE OBSTETRIQUE ET BIOLOGIE DE LA REPRODUCTION (2013)
Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review
Simona Ferraro et al.
JOURNAL OF CLINICAL PATHOLOGY (2013)
Serum levels of the ovarian cancer biomarker HE4 are decreased in pregnancy and increase with age
Richard G. Moore et al.
AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY (2012)
Does risk for ovarian malignancy algorithm excel human epididymis protein 4 and ca125 in predicting epithelial ovarian cancer: A meta-analysis
Fake Li et al.
BMC CANCER (2012)
External Validation of Diagnostic Models to Estimate the Risk of Malignancy in Adnexal Masses
Caroline Van Holsbeke et al.
CLINICAL CANCER RESEARCH (2012)
Subjective assessment by ultrasound is superior to the risk of malignancy index (RMI) or the risk of ovarian malignancy algorithm (ROMA) in discriminating benign from malignant adnexal masses
Toon Van Gorp et al.
EUROPEAN JOURNAL OF CANCER (2012)
Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass
Mona Aarenstrup Karlsen et al.
GYNECOLOGIC ONCOLOGY (2012)
Human epididymis protein 4 reference limits and natural variation in a Nordic reference population
Nils Bolstad et al.
TUMOR BIOLOGY (2012)
HE4 and CA125 as a diagnostic test in ovarian cancer: prospective validation of the Risk of Ovarian Malignancy Algorithm
T. Van Gorp et al.
BRITISH JOURNAL OF CANCER (2011)
The ROMA (Risk of Ovarian Malignancy Algorithm) for estimating the risk of epithelial ovarian cancer in women presenting with pelvic mass: is it really useful?
Martina Montagnana et al.
CLINICAL CHEMISTRY AND LABORATORY MEDICINE (2011)
A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2009)
Preoperative evaluation and triage of women with suspicious adnexal masses using risk of malignancy index
Christopher A. Enakpene et al.
JOURNAL OF OBSTETRICS AND GYNAECOLOGY RESEARCH (2009)
Cancer statistics, 2008
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2008)
The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass
Richard G. Moore et al.
GYNECOLOGIC ONCOLOGY (2008)
Simple ultrasound-based rules for the diagnosis of ovarian cancer
D. Timmerman et al.
ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2008)
Refining clinical diagnosis with likelihood ratios
DA Grimes et al.
LANCET (2005)
Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometriold ovarian carcinomas
R Drapkin et al.
CANCER RESEARCH (2005)
Share Paper
